Amgen Lung Cancer Drug Cuts Death Risk by 58%
A new drug combo from Amgen and AstraZeneca cuts the risk of death by 58% for patients with aggressive lung cancer.
Doctors face a tough fight against aggressive lung cancer. Patients often run out of good options. A new clinical trial brings fresh hope to these families.
Amgen tested its medicine with a cancer treatment from AstraZeneca. The two drugs attack tumors together. Patients on this combo cut their risk of death by 58%. They lived longer without the cancer spreading.
This win puts Amgen in a strong spot. Big clinical wins help companies earn swift approval from health regulators. They also open the door for steady sales growth.
Watch for more updates as this therapy moves toward wider use. Strong science creates real value for both patients and smart investors.
Source: CNBC
More from Biotech
